hematopoietic stem cells

[Scientific Reports] Sequencing analysis and human androgen receptor assays revealed that the majority of triple negative (TN)-essential thrombocythemia (ET) patients exhibited polyclonal hematopoiesis, suggesting a possibility of reactive thrombocytosis in TN-ET.

[Leukemia] The authors investigated the impact of PRC1.1 insufficiency on myelofibrosis. Transcriptome and chromatin immunoprecipitation sequence analysis showed the de-repression of PRC1.1 target genes in Pcgf1-deficient JAK2V617F hematopoietic progenitors and revealed Hoxa cluster genes as direct targets.

[EdiGene, Inc. (Business Wire, Inc.)] EdiGene, Inc. announced the first patient enrolled in multicenter Phase I clinical study of its investigational gene-editing hematopoietic stem cell therapy ET-01 for patients with transfusion dependent β-thalassemia at the Institute of Hematology and Blood Diseases Hospital.

[Jasper Therapeutics, Inc. (Business Wire, Inc.)] Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related myelodysplastic syndromes.

[Blood] Scientists reported that CUX1 had a critical early role in the DNA repair process in hematopoietic stem and progenitor cells. Mechanistically, CUX1 recruited the histone methyltransferase EHMT2 to DNA breaks to promote downstream H3K9 and H3K27 methylation, phosphorylated ATM retention, subsequent γH2AX focus formation and propagation, and, ultimately, 53BP1 recruitment.

[Blood Advances] Avelumab was tolerable and demonstrated antitumor activity in heavily pretreated patients with classical Hodgkin lymphoma (cHL), suggesting that PD-L1 blockade may be sufficient for therapeutic benefit in cHL.